X

Cell, Gene, Regenerative Medicine & Nucleic Acid (CGRN) Community

Cell, gene, regenerative medicine, and nucleic acid (CGRN) therapeutics are new from clinical pharmacology perspectives. The CGRN Community will focus on the translation science, clinical development, and life cycle management of these modalities with the consideration of relevant diseases, targets, and delivery systems. The Community welcomes all ASCPT members with different professional backgrounds, personal identities, and social-cultural origins.

The goals of the CGRN Community include:
  1. Connect members and resources within the CGRN field among scientists from academia, industry, health care, and regulatory.
  2. Engage CGRN professionals in interactive conversations to expand their knowledge base and improve competency in their position.
  3. Share information on state-of-the-art developments, best practices, and expert opinions to accelerate the development of safe and efficacious therapeutics.
  4. Influence scientific development in the field.
  5. Develop the next generation of scientists by providing learning tools, promoting publications, and recruiting members.

Join the LinkedIn group

Community Hosted Webinars:
Webinar recordings can be accessed using the members-only webinar library. Please note that you must be logged in as member to access this content:

  • Next-Generation CAR T Cell Development: Integrating Clinical Pharmacology and MIDD Approaches (Jan 26, 2026) Cell and Gene Therapy: Transforming Treatment Paradigms for Patient-Centric Care, ASCPT 2025 Annual Meeting Satellite Session (April 4, 2025)
  • Gene Therapy Breakthroughs for Rare Diseases: Insights, Learnings and Reflections on Quantitative Systems Pharmacology Approaches (Jan 2025)
  • Dose Selection for Adeno-Associated Virus (AAV) Gene Therapy: Recent Advances and Future Prospects (Dec 2024)
  • Best Practices, Considerations for Clinical Pharmacology & Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies (Jan 2024)
  • Leveraging Clinical Biomarkers with BIOiSIM’s AI-Enabled Technology to Stratify Patients and Predict Disease Severity and Progression (April 2024)
  • Unraveling the Code: Clinical Pharmacology Insights and MIDD Strategies in RNA-Based Oligonucleotide Drug Development (April 2024)
Ivy Dong

Ivy Dong, PhD

Community Chair

 

Shuai Dong

Shuai Dong, PhD

Community Vice Chair

 

Sojeong Yi

Sojeong Yi, PhD

Community Past Chair

 

Steering Committee

Kefeng Sun, PhD
Chao Han, PhD
Dhruvit Sutaria, PhD
Joy Hsu, PhD
Mike Liao, PhD
Noha Rayad, PhD
Satsuki Yamada, MD, PhD
Shirley Chang, PhD
Tao Long, PhD
Torbjörn Callréus, MD, PhD
Wendy Qiao, PhD
Jiawei Zhou, PhD
Million Tegenge, PhD
Lucia Wille, PhD

 

Photo Gallery
Recent News
Contact Us